The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.
P. J. Woll
Other Remuneration - Support for conference attendance
K. N. Moore
No relevant relationships to disclose
S. Bhatia
Research Funding - Immunogen
F. V. Fossella
Research Funding - Immunogen
L. C. Chen
No relevant relationships to disclose
M. O'Brien
No relevant relationships to disclose
P. Lorigan
No relevant relationships to disclose
S. D. Weitman
Consultant or Advisory Role - Immunogen
J. J. O'Leary
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
S. Zildjian
Employment or Leadership Position - Immunogen
E. Bulger
Employment or Leadership Position - Immunogen
R. Guild
Employment or Leadership Position - Immunogen
M. H. Shah
Research Funding - Immunogen